: In the phase 2 FORTE trial, transplant-eligible newly diagnosed multiple myeloma patients aged ≤65 years were randomized to (R1) carfilzomib-lenalidomide-dexamethasone followed by autologous stem cell transplantation (KRd-ASCT), twelve cycles of KRd (KRd12), or carfilzomib-cyclophosphamide-dexamethasone followed by ASCT (KCd-ASCT). Eligible patients were then randomized (R2) to maintenance with carfilzomib for 2 years plus lenalidomide until progression (KR) or lenalidomide alone until progression (R). With extended follow-up (median 99 months from R1 and 85 months from R2), KRd-ASCT significantly increased progression-free survival (PFS, median 98 months) versus KRd12 (median 70 months; HR 0.71, p=0.027) and KCd-ASCT (median 67 months; HR 0.66, p=0.006). A significant benefit in PFS2 was also observed versus both KRd12 (HR 0.65, p=0.02) and KCd-ASCT (HR 0.68, p=0.04) and in terms of overall survival (OS) versus KCd-ASCT (8-year OS: 76% vs 68%; HR 0.65, p=0.04). KR maintenance significantly improved PFS versus R (HR 0.67, p=0.02), with a time-dependent effect persisting up to two years after carfilzomib discontinuation; no differences in PFS2/OS were observed. KR significantly increased rate of measurable residual disease (MRD) conversion (sHR 0.47, p=0.03) during active treatment, and reduced MRD resurgence (sHR 0.53, p=0.001) versus R. Median duration of MRD negativity was 50.5 months in KR vs. 38 months in R arm. MRD-negative patients had significantly prolonged PFS with KR (HR 0.60, p=0.031); MRD-positive patients benefited from KR mainly during carfilzomib therapy (HR 0.46, p=0.05). The cumulative incidence of second primary malignancies was 6%. In conclusion, long-term follow-up confirms the high effectiveness of KRd-ASCT and KR maintenance. NCT02203643.
Carfilzomib-based strategies in transplant-eligible multiple myeloma: long-term follow-up of the phase 2 FORTE trial / Bertuglia, G., D'Agostino, M., Rota-Scalabrini, D., Belotti, A., Paris, L., Quaresima, M., More', S., Ballanti, S., Aquino, S., De Fabritiis, P., Fioritoni, F., Cea, M., Giuliani, N., Patriarca, F., Oliva, S., Gentile, M., Fazio, F., Zambello, R., Bringhen, S., Corradini, P., et al.. - In: BLOOD. - ISSN 1528-0020. - (2026). [10.1182/blood.2026035635]
Carfilzomib-based strategies in transplant-eligible multiple myeloma: long-term follow-up of the phase 2 FORTE trial
D'Agostino, Mattia;More', Sonia;
2026-01-01
Abstract
: In the phase 2 FORTE trial, transplant-eligible newly diagnosed multiple myeloma patients aged ≤65 years were randomized to (R1) carfilzomib-lenalidomide-dexamethasone followed by autologous stem cell transplantation (KRd-ASCT), twelve cycles of KRd (KRd12), or carfilzomib-cyclophosphamide-dexamethasone followed by ASCT (KCd-ASCT). Eligible patients were then randomized (R2) to maintenance with carfilzomib for 2 years plus lenalidomide until progression (KR) or lenalidomide alone until progression (R). With extended follow-up (median 99 months from R1 and 85 months from R2), KRd-ASCT significantly increased progression-free survival (PFS, median 98 months) versus KRd12 (median 70 months; HR 0.71, p=0.027) and KCd-ASCT (median 67 months; HR 0.66, p=0.006). A significant benefit in PFS2 was also observed versus both KRd12 (HR 0.65, p=0.02) and KCd-ASCT (HR 0.68, p=0.04) and in terms of overall survival (OS) versus KCd-ASCT (8-year OS: 76% vs 68%; HR 0.65, p=0.04). KR maintenance significantly improved PFS versus R (HR 0.67, p=0.02), with a time-dependent effect persisting up to two years after carfilzomib discontinuation; no differences in PFS2/OS were observed. KR significantly increased rate of measurable residual disease (MRD) conversion (sHR 0.47, p=0.03) during active treatment, and reduced MRD resurgence (sHR 0.53, p=0.001) versus R. Median duration of MRD negativity was 50.5 months in KR vs. 38 months in R arm. MRD-negative patients had significantly prolonged PFS with KR (HR 0.60, p=0.031); MRD-positive patients benefited from KR mainly during carfilzomib therapy (HR 0.46, p=0.05). The cumulative incidence of second primary malignancies was 6%. In conclusion, long-term follow-up confirms the high effectiveness of KRd-ASCT and KR maintenance. NCT02203643.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


